GIA
ONCT

Gladstone Institutional Advisory’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Gladstone Institutional Advisory’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-508
Closed -$50K – 448
2020
Q4 		$50K Buy
+508
New +$32.1K 0.01% 293

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Gladstone Institutional Advisory's ONCT Position: Q1 2021 in Review

Gladstone Institutional Advisory sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2021, closing a stake of 508 shares — an estimated $50K sold.

Gladstone Institutional Advisory first reported a position in ONCT in Q4 2020 and held it in 1 quarter. The position peaked at $50K in Q4 2020. 64 funds tracked by Wall St. Rank hold ONCT as of Q1 2021.

  • Gladstone Institutional Advisory reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Gladstone Institutional Advisory sold 508 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $50K.
  • Gladstone Institutional Advisory first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Gladstone Institutional Advisory's Oncternal Therapeutics, Inc. Common Stock position peaked at $50K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2021, filed 17 May 2021.